{"links":{"feed":"https://www.erudio.com/reports/incb161734-101-nct06179160/feed.json","html":"https://www.erudio.com/reports/incb161734-101-nct06179160","json":"https://www.erudio.com/reports/incb161734-101-nct06179160.json","markdown":"https://www.erudio.com/reports/incb161734-101-nct06179160.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"incb161734-101-nct06179160"}},"request":"https://www.erudio.com/contact?report=incb161734-101-nct06179160"},"offer":{"cited_clinicians":9,"cited_commentary_sources":18,"verified_hcp_statements":32,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":13},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"incb161734-101-nct06179160"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=incb161734-101-nct06179160","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/incb161734-101-nct06179160","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 32 verified statements · 16 from 9 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T22:04:34.998625Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":2,"title":"Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: INCB161734 pharmacokinetic (PK) in Plasma"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":10,"title":"Secondary endpoint: Objective Response Rate (ORR)"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":3,"title":"Secondary endpoint: Disease Control Response (DCR)"},{"claim_count":1,"coverage":"discussed","id":"T7","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":1,"title":"Secondary endpoint: Duration of Response (DOR)"},{"claim_count":6,"coverage":"discussed","id":"T8","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T9","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T10","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T11","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":3,"title":"ctDNA response and possible KRAS copy-number resistance"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Survival follow-up and six-month PFS reporting"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Trial visibility and choice among KRAS studies"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":6,"title":"Forward-looking PDAC positioning and development expectations"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Proposed appendix-cancer study with PD1 blockade"}],"counts":{"cited_clinicians":9,"cited_clinicians_by_role":{"physician":1,"physician, Gastroenterology":1,"physician, Medical oncology":7},"cited_physicians":9,"cited_sources":18,"claims_by_expression_type":{"comparison":3,"interpretation":6,"opinion":13,"question":2,"restatement":5,"uncertainty":1,"unspecified":2},"claims_by_kind":{"source_observation":32},"clinician_statements":16,"evidence_units":25,"findings":6,"organisational_accounts":1,"people_cited":16,"people_identity_verified":13,"people_total":16,"screened_sources":28,"verified_claims":32},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":1,"views":6},"limitations":4,"links":{"context":1,"support":10},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"media":3}},"title":"CRC: speakers note cetuximab combo activity; most see combos as needed","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-bdf03ba97a082e5362d7","claim-0ff8bfcbdea2199a6bd5","claim-45f4f25f262fd32ab8b5"],"clause":"most see combos as needed","holders":2},"cited_claim_ids":["claim-bdf03ba97a082e5362d7","claim-8901921cac188c73c6fd","claim-dc140fd78e99ff80f86e","claim-ed881678c93bab663059","claim-45f4f25f262fd32ab8b5"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 3 sources, all podcasts or videos","holder_line":"3 of the 3 named speakers in this finding hold this view; 2 of them hold its caveat, “most see combos as needed”"},{"cited_clinicians":6,"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":3,"views":6},"limitations":4,"links":{"context":0,"support":10},"ma_question":true,"named_voices":8,"passages":9,"sources":9,"sources_by_kind":{"commentary":9}},"title":"PDAC phase 1 combos: some clinicians see feasibility; a speaker weighs GI trade-offs","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-a3bdac2c1d9f2893a88a"],"clause":"a speaker weighs GI trade-offs","holders":1},"cited_claim_ids":["claim-805bcf4bdd33c5415ad3","claim-ba223637995b36cc3951","claim-5ad8c2b829e54d588cf2","claim-38d00241a3a466f147af","claim-2f143bded78fd997403a"],"clinicians":true,"holders":4,"speakers":8,"view":"reading"},"evidence_line":"10 statements from 8 speakers in 9 sources","holder_line":"4 of the 8 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 8 holds its caveat, “a speaker weighs GI trade-offs”"},{"cited_clinicians":5,"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":4,"views":7},"limitations":5,"links":{"context":0,"support":13},"ma_question":true,"named_voices":7,"passages":8,"sources":8,"sources_by_kind":{"commentary":8}},"title":"PDAC phase 1: most speakers highlight responses; a clinician awaits PFS/OS medians","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b2e8a3ffa9dad35975a7"],"clause":"a clinician awaits PFS/OS medians","holders":1},"cited_claim_ids":["claim-d873b895bd8ac82895cb","claim-b2e8a3ffa9dad35975a7","claim-dfdfc6e867c1331c259f","claim-1c0c51357688d947923a","claim-b2250437d753e8864cf7","claim-83b3e674d5367986914b","claim-5ad8c2b829e54d588cf2","claim-0cc6f23c56a53341e3aa","claim-754e166cc710052d545f"],"clinicians":false,"holders":6,"speakers":7,"view":"reading"},"evidence_line":"13 statements from 7 speakers in 8 sources","holder_line":"6 of the 7 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician awaits PFS/OS medians”"},{"cited_clinicians":0,"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"KRAS trial choice: a speaker asks why QTX3034 was chosen over other KRAS trials","title_holders":{"cited_claim_ids":["claim-f47be274db18171ab864"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":5,"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":7},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":6,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"KRAS: most speakers welcome development; a clinician expects a PDAC standard of care","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-0cc6f23c56a53341e3aa"],"clause":"a clinician expects a PDAC standard of care","holders":1},"cited_claim_ids":["claim-dfdfc6e867c1331c259f","claim-0cc6f23c56a53341e3aa","claim-7bb26e6f7d4a10e643f3","claim-38d00241a3a466f147af","claim-2f143bded78fd997403a"],"clinicians":false,"holders":5,"speakers":6,"view":"reading"},"evidence_line":"7 statements from 6 speakers in 6 sources","holder_line":"5 of the 6 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician expects a PDAC standard of care”"},{"cited_clinicians":1,"id":"F6","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Appendix cancer: a clinician proposes a trial, ideally with a PD1 inhibitor","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-eceef0bcb604591c8246"],"clause":"ideally with a PD1 inhibitor","holders":1},"cited_claim_ids":["claim-eceef0bcb604591c8246"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “ideally with a PD1 inhibitor”"}],"open_question":{"basis":"From findings F1 (9 statements from 3 speakers in 3 sources) and F5 (7 statements from 6 speakers in 6 sources)","cited_claim_ids":["claim-722d8b90a7c815adf61e","claim-bdf03ba97a082e5362d7","claim-0ff8bfcbdea2199a6bd5","claim-8901921cac188c73c6fd","claim-718d86fe9dbc6f316a7a","claim-dc140fd78e99ff80f86e","claim-ed881678c93bab663059","claim-45f4f25f262fd32ab8b5","claim-c8adedbdf2abbd5747e4","claim-7bb26e6f7d4a10e643f3"],"finding_ids":["F1","F5"],"question":"What do clinicians need to see on activity and tolerability from larger INCB161734–cetuximab cohorts and chemotherapy combinations to build on phase 1b findings in heavily pretreated KRAS G12D-mutant metastatic colorectal cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Interview speakers see stronger CRC activity with cetuximab combinations"},{"id":"section-2","level":2,"title":"X accounts welcome PDAC combination feasibility while one questions the backbone trade-off"},{"id":"section-3","level":2,"title":"X accounts welcome early PDAC activity but leave durability and resistance unresolved"},{"id":"section-4","level":2,"title":"One X account questions trial choice while an unnamed account highlights visibility"},{"id":"section-5","level":2,"title":"X accounts welcome further development; one predicts standard-of-care use in PDAC"},{"id":"section-6","level":2,"title":"One clinician proposes appendix-cancer research with PD1 blockade"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T2","label":"Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T3","label":"Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation"},{"findings":[],"id":"T4","label":"Secondary endpoint: INCB161734 pharmacokinetic (PK) in Plasma"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":4},{"id":"F5","shared_claims":1}],"id":"T5","label":"Secondary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T6","label":"Secondary endpoint: Disease Control Response (DCR)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T7","label":"Secondary endpoint: Duration of Response (DOR)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T8","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2}],"id":"T9","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":2}],"id":"T10","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T11","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T22:04:34.998625Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T22:27:22Z","record_hash":"21bfc956d515c713ff61f9f14e96f4c037678c5c0c971e13942826d59ab9980d","release_hash":"7e2ce92164533c68626f4bf382b671ec14e6b84af323b4cf4d5a6ff9f8b10512","report_id":"erudio-nct06179160","run_id":"929c67ae-2978-47a3-84a5-b5d76235a207","schema_version":"5.0","slug":"incb161734-101-nct06179160","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For INCB161734-101, a speaker described in the sources as presenting the trial favors cetuximab-combination development in CRC given limited single-agent activity, without randomized proof of benefit. Medical oncologists consider chemotherapy combinations feasible in PDAC; a speaker tentatively favors FFXN for potentially lower GI toxicity. Durability remains uncertain. The sources place INCB161734 phase 1 PDAC findings at ASCO GI 2026, with updated PDAC combination results at ESMO 2026.","examples":[],"meta_description":"28 sources screened · 32 verified statements (16 from clinicians verified by NPI or staff page) from 18 sources · 6 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T22:27:22Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":28},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on an alternative treatment considered during KRAS-targeted trial selection.","14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 17 sources about other trials or topics are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Reposts and quoted redistribution do not establish independent endorsement.","Most cited remarks describe phase 1 INCB161734 or KRAS G12D inhibitor experience in PDAC or CRC without naming NCT06179160. They are treated as contextual commentary on its clinical question, not automatically reassigned as outcomes documented for that registry number.","Search coverage may miss unnamed trial references or transcription variants, so an issue absent from this report may still have been discussed elsewhere.","No publication specific to NCT06179160 was identified, no protocol was listed in ClinicalTrials.gov, and no exact INCB161734 label was identified. Some related regulatory material was not assessed; this does not establish approval status.","Small early cohorts, different pretreatment histories, doses, efficacy denominators and reporting timepoints prevent pooling or conclusions about comparative treatment effects.","A speaker's use of SAEs for mostly grade 1/2 events, unclear allocation of percentages to cohorts, and qualitative safety descriptions elsewhere limit standardized interpretation of tolerability.","The statements do not establish mature durability, a validated survival-surrogate role for ctDNA response, or a causal KRAS copy-number resistance mechanism.","Development forecasts, first-line positioning, best-in-class language and the appendix-cancer proposal are opinions or proposed research directions, not established treatment benefits."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-11-02","start":"2023-12-21"},"retrieval_snapshot":"2026-11-20T21:17:21.300291Z","timeline":[{"count":1,"week":"2023-W51"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2026-W01"},{"count":7,"week":"2026-W02"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W43"},{"count":4,"week":"2026-W44"},{"count":2,"week":"2026-W45"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06179160:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06179160:context","quote_policy":"short_quote_link_out"},{"id":"openfda:8bc6397e-4bd8-4d37-a007-a327e4da34d9:20260416","quote_policy":"short_quote_link_out"},{"id":"openfda:109648d0-d30a-42fc-8273-39cb1540a751:20260518","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3mbzc4l55xc2x","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1737952168219709607:242b3d77-c198-4043-8f51-94c33e1a1620","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915481559916040272:0e6e32cf-2fa8-4624-96d2-f53f6ffeff14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915805757792043297:d0f7094b-8846-4592-bcb1-61ff277beaf2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980248037583908911:85097b48-ee3c-400d-9638-cbb3afa54bbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985385927448150302:8f8de8ea-491f-457e-82d5-a0b05ffc03ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2007807419666047037:2513609b-def6-423d-a13e-cca93457735e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2008424380334743742:5c8d29fb-14ac-4bf4-9d25-fe829f5d614d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009665016996250054:1b311900-7a60-42e1-9375-7087e9f99a23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009665256768069760:0a83016e-7be9-48f2-bc36-884aa40c8a07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009665320697626911:84043c7e-6e5a-4f8d-94b5-2de52b899f53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009665384790831393:5fa7aca8-4821-498f-8ae1-d8183ac36e18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009665675552600186:c8e913cc-b1a4-4c41-8570-edd07e8d2225","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009672231769772279:72363bd2-3044-49df-abe9-15f62a77e452","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009673141858304503:06b0d6ab-cc3c-4dcb-95df-8fde30bedb6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009674582392029509:c27dc438-c34a-4750-84ac-96554b24ff77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010014476792410240:8360335d-fa98-47ef-b069-0451ee7db00e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010064482442351073:796cb3f7-e46f-4a83-946f-65fd2cd18bc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2023853602314612744:487c91f1-ae19-42ce-8263-4164610b0ea5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114264416858374306:41942744-6648-40b8-9711-a5e5fcb9ac30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114285642494435564:ddb5e864-5005-4dbb-b196-340ca36b4564","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114370585606410361:4c99d9a0-d236-48e0-919a-761e9f3c4dd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722228151460020:cadd3d63-fed3-4c39-9d8c-07d365e64362","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722312222015894:83076fdb-358d-48f5-9ac8-39b46b667d4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114724395545731428:366f4dac-ba5e-42d8-ac35-03f6e23a7970","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CXbEBUArLRo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NoqqJFfZBTQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mZ5NKzI0uls","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2026-11-02","start":"2023-12-21"},"retrieval_snapshot":"2026-11-20T21:17:21.300291Z","timeline":[{"count":1,"week":"2023-W51"},{"count":2,"week":"2025-W17"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W01"},{"count":13,"week":"2026-W02"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W25"},{"count":3,"week":"2026-W43"},{"count":4,"week":"2026-W44"},{"count":2,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":9}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"INCB161734","slug":"incb161734"},{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"brand_names":["Zynyz"],"label":"retifanlimab","slug":"retifanlimab"},{"reason":"Unmapped registry intervention: gemnabp","status":"unmapped"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"inca33890","slug":"inca33890"}],"indications":[{"reason":"Unmapped registry condition: Solid Tumors","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"INCB161734-101","aliases":["INCB161734-101","A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation"],"brief_title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Solid Tumors"],"display_condition":"KRAS G12D-mutated advanced or metastatic solid tumors","display_interventions":[["INCB161734"],["INCB161734","cetuximab"],["INCB161734","retifanlimab"]],"enrollment":{"count":710,"type":"ESTIMATED"},"interventions":[{"name":"INCB161734","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cetuximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Retifanlimab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"GEMNabP","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"mFOLFIRINOX","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"FOLFOX","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"FOLFIRI","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"INCA33890","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06179160","official_title":"A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.","measure":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 28 days"},{"description":"Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab and retifanlimab.","measure":"Number of participants with Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to 2 years and 90 days"},{"description":"Number of participants with TEAEs leading to dose modification or discontinuation.","measure":"Number of participants with TEAEs leading to dose modification or discontinuation","timeFrame":"Up to 2 years and 90 days"}],"registered_date":{"date":"2023-12-21","type":"ACTUAL"},"registry_last_updated":"2026-07-22","registry_url":"https://clinicaltrials.gov/study/NCT06179160","short_name":"INCB161734-101","short_name_basis":"canonical_name","sponsor":"Incyte Corporation","start_date":{"date":"2024-01-04","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1","study_ids":[{"id":"INCB161734-101","type":"sponsor_study_id"},{"domain":"EU CT Number","id":"2023-507091-47-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}